April 19, 2014 12:13 PM ET

Biotechnology

Company Overview of X-Chem, Inc.

Company Overview

X-Chem, Inc. operates as a subsidiary of Pharmaceutical Product Development Inc.

100 Beaver Street Suite 101

Waltham, MA 02453

United States

Phone:

781-419-6900

Fax:

781-419-6903

Key Executives for X-Chem, Inc.

X-Chem, Inc. does not have any Key Executives recorded.

X-Chem, Inc. Key Developments

X-Chem and PsyBrain Establish Partnership to Discover New Psychiatric Medicines

X-Chem, Inc. announced it has entered into an partnership with PsyBrain, Inc. to discover new drugs for treating psychiatric illnesses. Under the terms of the agreement, X-Chem will conduct drug discovery efforts to identify lead compounds for therapeutic targets provided by PsyBrain. X-Chem will receive research and development funding for each project. Each X-Chem program licensed by PsyBrain is eligible for pre-clinical, clinical and sales milestones. Financial details were not disclosed.

X-Chem, Inc. Enters Expanded Global Drug Discovery Collaboration with AstraZeneca

X-Chem, Inc. announced it has entered into an expanded global drug discovery collaboration with AstraZeneca across all of the pharmaceutical company's therapeutic areas and multiple target classes. The companies had entered into a previous collaboration in May of 2012. AstraZeneca recently elected to license three drug discovery programs resulting from that effort, directed at, respectively, an oncology protein-protein interaction (PPI) target, a respiratory/inflammation PPI target, and an antibacterial target. AstraZeneca has opted to extend the initial research collaboration from two to five years. X-Chem will conduct drug discovery on at least 10 therapeutic targets per year going forward. Under the terms of the new agreement, X-Chem will receive committed research and development funding for each project. Each X-Chem program licensed by AstraZeneca is eligible for pre-clinical, clinical and sales milestones in the aggregate amount of up to $26 million. In addition, X-Chem will receive significant royalties for each successfully commercialized drug that results from a licensed collaboration program.

X-Chem Inc. Announces License of First Three Drug Candidates to AstraZeneca

X-Chem Inc. has scored license agreements for three of its drug candidates with drug giant AstraZeneca for undisclosed amounts. The candidates licensed by AstraZeneca are a cancer drug, a respiratory/inflammation drug and an antibacterial. While the company is not releasing financial information regarding the license agreement, it reported that the payment to X-Chem includes an upfront payment and research funding, as well as milestone payments for discovery and clinical development "commensurate with the innovative nature of the research and significant unmet medical need of the disease indications.

Similar Private Companies By Industry

Company Name Region
GeneWize Life Sciences, Inc. United States
Koronis Pharma, Inc. United States
Hyperion Biotechnology, Inc. United States
EpiCypher, Inc. United States
Phylos, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact X-Chem, Inc., please visit www.x-chemrx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.